GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

SciClone Pharmaceuticals (Holdings) 6600.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

50.30

+2.28%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2023

Revenue

CN¥3.16bn

FY2017FY2023

Net income

CN¥1.12bn

FY2017FY2023

Free cash flow

CN¥1.33bn

FY2017FY2023

Shareholders' equity

CN¥3.27bn

FY2017FY2023

Income statement

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017
RevenueCN¥3.16bnCN¥2.75bnCN¥2.52bnCN¥1.92bnCN¥1.71bnCN¥1.41bnCN¥1.21bn
Gross profitCN¥2.36bnCN¥2.07bnCN¥1.93bnCN¥1.49bnCN¥1.31bnCN¥1.11bnCN¥1.03bn
Research and developmentCN¥170.3mCN¥123.5mCN¥133.9mCN¥74.9mCN¥87.4mCN¥77.0mCN¥82.3m
Operating incomeCN¥1.26bnCN¥1.11bnCN¥1.04bnCN¥807.4mCN¥657.4mCN¥529.7mCN¥228.3m
Net incomeCN¥1.12bnCN¥855.4mCN¥923.4mCN¥753.7mCN¥614.6mCN¥535.1mCN¥19.6m
Diluted earnings per share1.721.211.331.350.910.790.03

Balance sheet

At each fiscal year end

FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assetsCN¥4.00bnCN¥4.32bnCN¥4.06bnCN¥2.88bnCN¥1.85bnCN¥1.30bnCN¥1.43bn
Cash and short-term investmentsCN¥2.22bnCN¥1.87bnCN¥2.19bnCN¥1.19bnCN¥1.04bnCN¥284.7mCN¥611.1m
Total liabilitiesCN¥735.2mCN¥1.33bnCN¥1.75bnCN¥2.57bnCN¥320.6mCN¥253.4mCN¥467.8m
DebtCN¥32.8mCN¥852.6mCN¥1.17bnCN¥1.96bnCN¥26.5mCN¥39.6mCN¥38.8m
Shareholders' equityCN¥3.27bnCN¥2.99bnCN¥2.32bnCN¥311.9mCN¥1.53bnCN¥1.04bnCN¥959.9m
Shares outstanding650m708m695m559m678m678m678m

Cash flow

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operationsCN¥1.40bnCN¥1.18bnCN¥1.03bnCN¥981.0mCN¥1.03bnCN¥167.4mCN¥153.8m
Capital spending−CN¥77.6m−CN¥196.1m−CN¥190.8m−CN¥469.4m−CN¥32.6m−CN¥24.8m−CN¥10.7m
Free cash flowCN¥1.33bnCN¥987.4mCN¥838.6mCN¥511.6mCN¥999.0mCN¥142.7mCN¥143.1m
Dividends paid−CN¥215.0m−CN¥205.6m−CN¥827.3m————

Latest quarters

By quarter end

Dec 2023Jun 2023Dec 2022Jun 2022Dec 2021Jun 2021Dec 2020Sept 2020
RevenueCN¥1.55bnCN¥1.60bnCN¥1.27bnCN¥1.48bnCN¥1.19bnCN¥1.33bnCN¥334.4mCN¥1.58bn
Gross profitCN¥1.16bnCN¥1.19bnCN¥936.4mCN¥1.13bnCN¥887.1mCN¥1.05bnCN¥252.3mCN¥1.24bn
Operating incomeCN¥505.5mCN¥752.1mCN¥389.4mCN¥717.0mCN¥350.1mCN¥690.5mCN¥51.7mCN¥755.7m
Net incomeCN¥491.7mCN¥630.2mCN¥323.2mCN¥532.2mCN¥300.7mCN¥622.7mCN¥63.9mCN¥689.8m
Diluted earnings per share0.760.960.460.750.420.920.311.02
Cash from operationsCN¥824.0mCN¥579.0mCN¥659.0mCN¥523.0mCN¥721.0mCN¥308.0mCN¥171.0mCN¥809.0m
Capital spending−CN¥76.0m−CN¥1.0m−CN¥195.0m—−CN¥18.0m−CN¥172.0m−CN¥152.0m−CN¥316.0m
Free cash flowCN¥748.0mCN¥578.0mCN¥464.0m—CN¥703.0mCN¥136.0mCN¥19.0mCN¥493.0m
Total assetsCN¥4.00bnCN¥4.18bnCN¥4.32bnCN¥4.33bnCN¥4.06bnCN¥3.85bnCN¥2.88bnCN¥2.81bn
Cash and short-term investmentsCN¥2.00bnCN¥1.81bnCN¥1.87bnCN¥2.59bnCN¥2.19bnCN¥1.99bnCN¥1.19bnCN¥1.25bn
DebtCN¥19.8mCN¥433.4mCN¥422.0mCN¥815.1mCN¥773.3mCN¥1.17bnCN¥1.17bnCN¥1.63bn
Shareholders' equityCN¥3.27bnCN¥2.81bnCN¥2.99bnCN¥2.58bnCN¥2.32bnCN¥1.93bnCN¥311.9mCN¥166.0m

Financial ratios

Data as of 27 Sept 2026

FY2025FY2024FY2023FY2022
Gross margin54.0%51.7%50.4%34.3%
Operating margin-4.9%0.7%-3.3%-30.8%
Net margin-2.7%-0.5%-3.6%-31.7%
Return on equity-1.4%-1.6%-8.3%-41.7%
Return on assets-1.1%-0.7%-4.4%-25.5%
Free cash flow yield1.3%-0.2%——
Revenue growth43.8%33.4%66.5%—
Earnings growth682.0%-81.2%-81.2%—
Current ratio5.58x1.84x2.18x2.70x
Debt to equity0.07x0.60x0.22x0.25x
Equity ratio76.7%43.6%52.4%61.1%
Interest coverage-10.41x0.93x-6.82x-34.89x
R&D as a share of sales15.2%18.4%19.5%22.5%
Buybacks as a share of market value-89.6%———

Growth per year

Compound annual rate

3 years5 years10 years
Revenue18.0%17.5%—
Operating income15.9%18.9%—
Net income14.2%16.0%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin75.0%75.9%76.3%—
Operating margin40.0%40.7%40.1%—
Net margin33.5%35.3%35.7%—

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 2 Jun 2023.

FY2023FY2022
Paid in the year0.390.35

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.